Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients

Table 4

Within-group changes in selected parameters of diabetic foot ulcer patients over 60 days of the trial. Data are mean differences* (95% CI).

Allocated group at baseline	Resveratrol group (𝑛=14)	Placebo group (𝑛=10)
Peak planter pressure, kPa	−13.07 (−26.78, 0.64)	−0.30 (−14.95, 14.35)
Fasting plasma glucose, mg/dL	31.57 (3.45, 59.69)	19.70 (−27.17, 66.57)
Plasma insulin, 𝜇IU	1.29 (−1.48, 4.05)	0.89 (9.46, −5.88)
Plasma fibrinogen, mg/dL	118.93 (12.29, 225.56)	20.70 (−235.48, 276.88)
CRP, g/L^†	−0.25 (−1.50, 1.50)	−0.05 (−2.50, 1.40)
Total cholesterol, mg/dL	17.29 (3.52, 31.05)	32.60 (4.29, 60.91)
HDL cholesterol, mg/dL	−1.43 (−6.27, 3.42)	3.40 (−0.11, 6.91)
LDL cholesterol, mg/dL	20.0 (6.2, 33.8)	23.80 (−1.36, 48.96)

∗Baseline-60 days.
†Median difference with robust CIs.